Cargando…

C9orf72 gene networks in the human brain correlate with cortical thickness in C9-FTD and implicate vulnerable cell types

INTRODUCTION: A hexanucleotide repeat expansion (HRE) intronic to chromosome 9 open reading frame 72 (C9orf72) is recognized as the most common genetic cause of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and ALS-FTD. Identifying genes that show similar regional co-expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broce, Iris J., Sirkis, Daniel W., Nillo, Ryan M., Bonham, Luke W., Lee, Suzee E., Miller, Bruce, Castruita, Patricia, Sturm, Virginia E., Sugrue, Leo S., Desikan, Rahul S., Yokoyama, Jennifer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370095/ https://www.ncbi.nlm.nih.gov/pubmed/37503230 http://dx.doi.org/10.1101/2023.07.17.549377

Ejemplares similares

Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
por: Sattler, Rita, et al.
Publicado: (2023)

The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD
por: Freibaum, Brian D., et al.
Publicado: (2017)

Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD
por: Mayl, Keith, et al.
Publicado: (2021)

Breakdown of the central synapses in C9orf72-linked ALS/FTD
por: Ghaffari, Layla T., et al.
Publicado: (2022)

CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD
por: Pickles, Sarah, et al.
Publicado: (2023)

Unraveling the Role of RNA Mediated Toxicity of C9orf72 Repeats in C9-FTD/ALS
por: Kumar, Vijay, et al.
Publicado: (2017)

Modifiers of C9orf72 DPR toxicity implicate nucleocytoplasmic transport impairments in c9FTD/ALS
por: Jovičić, Ana, et al.
Publicado: (2015)

Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion
por: Fong, Jamie C, et al.
Publicado: (2012)

Structure of the C9orf72 Arf GAP complex haploinsufficient in ALS and FTD
por: Su, Ming-Yuan, et al.
Publicado: (2020)

Emerging Perspectives on Dipeptide Repeat Proteins in C9ORF72 ALS/FTD
por: Schmitz, Alexander, et al.
Publicado: (2021)

Moderate intrinsic phenotypic alterations in C9orf72 ALS/FTD iPSC-microglia despite the presence of C9orf72 pathological features
por: Lorenzini, Ileana, et al.
Publicado: (2023)

Radiogenomics of C9orf72 Expansion Carriers Reveals Global Transposable Element Derepression and Enables Prediction of Thalamic Atrophy and Clinical Impairment
por: Bonham, Luke W., et al.
Publicado: (2023)

A familial FTD associated with C9orf72 repeat expansion and dysplastic gangliocytoma
por: Kero, Mia, et al.
Publicado: (2013)

The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD
por: Suzuki, Naoki, et al.
Publicado: (2013)

The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD
por: Solje, Eino, et al.
Publicado: (2015)

C9ORF72 and the FTD-ALS spectrum: A systematic review of neuroimaging studies
por: Prado, Laura de Godoy Rousseff, et al.
Publicado: (2015)

Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
por: Coyne, Alyssa N., et al.
Publicado: (2021)

Hypothesis and Theory: Roles of Arginine Methylation in C9orf72-Mediated ALS and FTD
por: Gill, Anna L., et al.
Publicado: (2021)

Altered Phase Separation and Cellular Impact in C9orf72-Linked ALS/FTD
por: Solomon, Daniel A., et al.
Publicado: (2021)

C9ORF72 knockdown triggers FTD-like symptoms and cell pathology in mice
por: Lopez-Herdoiza, Maria-Belen, et al.
Publicado: (2023)

C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD?
por: Braems, Elke, et al.
Publicado: (2020)

Targeting RNA G‐quadruplexes as new treatment strategy for C9orf72 ALS/FTD
por: Schludi, Martin H, et al.
Publicado: (2017)

Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD
por: Moens, Thomas G., et al.
Publicado: (2018)

RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3
por: Ramesh, Nandini, et al.
Publicado: (2020)

Metformin treatment of the C9orf72 ALS/FTD mouse: Almost too good for words
por: Rosbash, Michael
Publicado: (2020)

C9orf72 and the Care of the Patient With ALS or FTD: Progress and Recommendations After 10 Years
por: Roggenbuck, Jennifer
Publicado: (2020)

Thalamic and Cerebellar Regional Involvement across the ALS–FTD Spectrum and the Effect of C9orf72
por: Bocchetta, Martina, et al.
Publicado: (2022)

An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD
por: Bauer, Claudia S., et al.
Publicado: (2022)

Propranolol reduces the accumulation of cytotoxic aggregates in C9orf72-ALS/FTD in vitro models
por: Seidel, Mira, et al.
Publicado: (2023)

Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood
por: Belzil, Veronique V., et al.
Publicado: (2013)

Nuclear export and translation of circular repeat-containing intronic RNA in C9ORF72-ALS/FTD
por: Wang, Shaopeng, et al.
Publicado: (2021)

Divergent single cell transcriptome and epigenome alterations in ALS and FTD patients with C9orf72 mutation
por: Li, Junhao, et al.
Publicado: (2023)

Neuroimaging features of C9ORF72 expansion
por: Yokoyama, Jennifer S, et al.
Publicado: (2012)

Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD
por: Krishnan, Gopinath, et al.
Publicado: (2022)

A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD
por: Hukema, Renate K, et al.
Publicado: (2014)

Gyrification abnormalities in presymptomatic c9orf72 expansion carriers
por: Caverzasi, Eduardo, et al.
Publicado: (2019)

Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective
por: Fernandes, Stephanie A., et al.
Publicado: (2013)

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy
por: Martier, Raygene, et al.
Publicado: (2019)

A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD
por: Esanov, Rustam, et al.
Publicado: (2017)

Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies
por: Balendra, Rubika, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nnj5s8i4ku59rvt8iggvvcfjs2